A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

Sanjay Goel, Kavita Desai, Manuel MacApinlac, Scott Wadler, Gary Goldberg, Abbie Fields, Mark Einstein, Fabio Volterra, Benny Wong, Russell Martin, Sridhar Mani

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers'. Together they form a unique fingerprint.

Medicine & Life Sciences